Risk factor
Good trading liquidity
Profitability factor
Very low or no dividends
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Steven Cohen | Point72 Asset Management, L.P. | 0.0% | -0.00% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.0% | +0.00% |
About
M/I Homes, Inc. (MHO), along with its affiliated companies, constructs single-family residences across a broad geographical area, including Ohio, Indiana, Illinois, Minnesota, Michigan, Florida, Texas, North Carolina, and Tennessee. Its operations are divided into three primary segments: Northern Homebuilding, Southern Homebuilding, and Financial Services. Under the M/I Homes brand, the company engages in the entire process of home development, from conceptual design and construction to marketing and sales. It caters to a diverse clientele, encompassing first-time purchasers, millennials, those upgrading their homes, empty-nesters, and luxury market consumers, offering both detached single-family houses and attached townhouses. Beyond building, M/I Homes acquires raw land, transforming it into ready-to-build lots. These developed parcels are then utilized for its own single-family home construction projects or sold to external parties. Furthermore, its financial services division facilitates homeownership by originating and selling mortgage loans. This segment also operates as a title insurance provider, offering policies, conducting examinations, and managing closing services for individuals buying M/I Homes properties. Originally established in Columbus, Ohio, in 1976, the company was initially named M/I Schottenstein Homes, Inc. It adopted its current name, M/I Homes, Inc., in January 2004.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA, overpri
Target Price
The average target price of MHO is 172 and suggests 13.1% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation